The SITC 2017 Microlearning: Clinical Trials - New Agents Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.
The Clinical Trials - New Agents series contains four modules.
Module 1: First-in-Human Study With Intratumoral Administration of a CD40 Agonistic Antibody: Preliminary Results With ADC-1013/JNJ-64457107 in Advanced Solid Malignancies
Peter Ellmark, PhD - Alligator Bioscience
Module 2: Initial Results from Phase 1 Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with NSCLC Refractory or Resistant to Prior Anti–PD-1/Anti–PD-L1 Agents
James L. Gulley, MD, PhD, FACP - National Cancer Institute
Module 3: A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients (pts) with Advanced Solid Tumors
Glen J. Weiss, MD - Western Regional Medical Center Inc.
Module 4: A Dual and Opposing Role for Tumor Intrinsic Type-II Interferon Sensing in Tumor Establishment and Acquired Resistance
Jason Williams, BS - University of Chicago
These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.
Course Available Beginning: August 16, 2018
Upon completion of this activity, participants will be able to:
- Describe the immune mechanisms that new immunotherapy agents are targeting.
- Outline how new IO agents work to circumvent cancer immune resistance mechanisms.
- Define the immune response generated by new IO agents.